NCT02215993 - Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis | Biotech Hunter

Enrollment

50

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

October 31, 2014

Conditions

Acute Coronary SyndromePlatelet Function

Interventions

DRUG

Prasugrel

After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.

DRUG

Ticagrelor

After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.

Trial Locations (1)

04024-002

Federal University of São Paulo, São Paulo